Drugmaker Eli Lilly said Thursday its COVID-19 antibody drug can prevent illness in residents and staff of nursing homes and other long-term care locations.It's the first major study to show such a treatment may prevent disease.Residents and staff who got the drug had up to a 57% lower risk of getting COVID-19 compared to others at the same facility who got a placebo, the drugmaker said.
Among nursing home residents only, the risk was reduced by up to 80%.The study involved more than 1,000 residents and staff at nursing homes and other long-term care locations.
The research was conducted with the National Institutes of Health. Results were released in a press release and the company said it would publish results in a journal soon.The Food.